Senti Biosciences Holdings (SNTI) Cash from Financing Activities (2021 - 2025)

Senti Biosciences Holdings' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $11.0 million for Q4 2025.

• In Q4 2025, Cash from Financing Activities fell 78.48% year-over-year to $11.0 million; the TTM figure through Dec 2025 stood at $11.8 million (down 78.11% YoY), while the FY2025 annual figure was $11.8 million, down 78.11% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $11.0 million, up from $124000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $232.0 million in Q2 2021, with the low at -$485000.0 in Q3 2022.
• The 5-year median for Cash from Financing Activities is $876000.0 (2022), against an average of $51.8 million.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities tumbled 100.21% in 2022, then jumped 10708.7% in 2024.
• Senti Biosciences Holdings' Cash from Financing Activities stood at $232.0 million in 2021, then sank by 99.62% to $876000.0 in 2022, then sank by 36.53% to $556000.0 in 2023, then soared by 9124.82% to $51.3 million in 2024, then slumped by 78.48% to $11.0 million in 2025.
• Business Quant data shows SNTI's Cash from Financing Activities at $11.0 million in Q4 2025, $124000.0 in Q3 2025, and $1.0 million in Q2 2025.